{"name":"Xuanzhu Biopharmaceutical Co., Ltd.","slug":"xuanzhu-biopharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"XZP-3287+ Letrozole/Anastrozole","genericName":"XZP-3287+ Letrozole/Anastrozole","slug":"xzp-3287-letrozole-anastrozole","indication":"Hormone receptor-positive breast cancer (postmenopausal women)","status":"phase_3"},{"name":"Placebo + Letrozole/Anastrozole","genericName":"Placebo + Letrozole/Anastrozole","slug":"placebo-letrozole-anastrozole","indication":"Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women","status":"phase_3"},{"name":"XZP-3287+Fulvestrant","genericName":"XZP-3287+Fulvestrant","slug":"xzp-3287-fulvestrant","indication":"Advanced breast cancer","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"XZP-5610 Tablet for \"Part C2\"","genericName":"XZP-5610 Tablet for \"Part C2\"","slug":"xzp-5610-tablet-for-part-c2","indication":"Rheumatoid Arthritis","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Anelazol Sodium Enteric-coated Tablets","genericName":"Anelazol Sodium Enteric-coated Tablets","slug":"anelazol-sodium-enteric-coated-tablets","indication":"Allergic rhinitis","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"XZP-3621","genericName":"XZP-3621","slug":"xzp-3621","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"XZP-3287+ Letrozole/Anastrozole","genericName":"XZP-3287+ Letrozole/Anastrozole","slug":"xzp-3287-letrozole-anastrozole","phase":"phase_3","mechanism":"XZP-3287 combined with aromatase inhibitors (letrozole or anastrozole) blocks estrogen production to treat hormone receptor-positive breast cancer.","indications":["Hormone receptor-positive breast cancer (postmenopausal women)"],"catalyst":""},{"name":"XZP-5610 Tablet for \"Part C2\"","genericName":"XZP-5610 Tablet for \"Part C2\"","slug":"xzp-5610-tablet-for-part-c2","phase":"marketed","mechanism":"Small molecule","indications":["Rheumatoid Arthritis","Osteoarthritis","Ankylosing Spondylitis","Polyarticular Juvenile Idiopathic Arthritis","Tendonitis"],"catalyst":""},{"name":"Anelazol Sodium Enteric-coated Tablets","genericName":"Anelazol Sodium Enteric-coated Tablets","slug":"anelazol-sodium-enteric-coated-tablets","phase":"marketed","mechanism":"Anelazol sodium is an anti-inflammatory agent that inhibits leukotriene synthesis and reduces inflammatory mediator production.","indications":["Allergic rhinitis","Asthma","Inflammatory bowel conditions"],"catalyst":""},{"name":"Placebo + Letrozole/Anastrozole","genericName":"Placebo + Letrozole/Anastrozole","slug":"placebo-letrozole-anastrozole","phase":"phase_3","mechanism":"Letrozole and Anastrozole are aromatase inhibitors that block the enzyme responsible for converting androgens to estrogens, thereby reducing estrogen levels in the body.","indications":["Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women","Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women"],"catalyst":""},{"name":"XZP-3287+Fulvestrant","genericName":"XZP-3287+Fulvestrant","slug":"xzp-3287-fulvestrant","phase":"phase_3","mechanism":"XZP-3287+Fulvestrant is a combination of XZP-3287 and Fulvestrant, which works by inhibiting the estrogen receptor.","indications":["Advanced breast cancer"],"catalyst":""},{"name":"XZP-3621","genericName":"XZP-3621","slug":"xzp-3621","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxOdE5NX1ktUmkwcGhIa21YWlJMS1loeVVVMjBXX3NETUN6M3NqWDFKemN6MnNJRjE2ZmE3RVVEQlZIZ0Vvb3hYMFMwU1pEVnY0Y2d4cmlfTWRRTjY1ZG1yNEVDRUZoXzdNaERRb29ucnppM19GdFVRalhaRjFPVm4ya25EOF94cG9rcWdzNFZtcUpPUVdoUkh1QUpZMExWV1FoXzZWcXdHMzEyeVdVVFNId3ZiUlZEbC1jVUZ3VXdjdy1fV2dIVG14WkhtX0oxTWpXNEdMRWhjM09NclFkaHhuTVN6Z3pkTUMzWk5yMlJUQmNoWHFv?oc=5","date":"2026-03-08","type":"pipeline","source":"minichart.com.sg","summary":"Xuanzhu Biopharm Shares Included in Hong Kong Stock Connect, Boosting Sihuan Pharmaceutical’s Market Value and Liquidity 12 - minichart.com.sg","headline":"Xuanzhu Biopharm Shares Included in Hong Kong Stock Connect, Boosting Sihuan Pharmaceutical’s Market Value and Liquidity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxORmlhY0RLUjIzRlVtX2V5dkFwaDhFNGhBV1hfQmhBSV8yRFpiNEU0SmwtWVBLal9MQmtQVUJ1TEVxUG40eUdKdEQxMFBGMGE2NGhVSGg4aS10czBNV1pSamRiN1hpZGNCWjc3cVd5SV9pYk41QVpEVllsYkJqRG9NNHF3Sjk1S21EaWRDZ3pYV094ejNqNi1OUWxEWGUyQ3A3d3VDQkdoZU9qV2hGdjc5TXpkTGlZUkk5NVd5eGFTSG1LQ2psM0hpdHBvWF9tLW15X0RjUkVOVVplekhLMkUwTHh0Q211U3c?oc=5","date":"2026-02-22","type":"pipeline","source":"minichart.com.sg","summary":"Xuanzhu Biopharm Added to Hang Seng Composite Index, Boosting Sihuan Pharmaceutical’s Innovative Drug Profile 123 - minichart.com.sg","headline":"Xuanzhu Biopharm Added to Hang Seng Composite Index, Boosting Sihuan Pharmaceutical’s Innovative Drug Profile 123","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQLXBiSWhQb3FPNHlfRUlYejBhYlpTOU1Hb2FsckpkVjBBQkU2RkUwN2FtLVRyNE1COExWYlYySkd1dHFudzJOSkppSjlHZS1WRHJCX3JhWTFHcUJtczBJWERPRWR0RE1DVFMzUHNwQzdWNXlCNHMwS04yWWItQkU3Q0VTZmNpVjhtX2owbjlRbnZaMzh3aS12cUNIRGRrM1d5Xy1DaGl3TFFncHc?oc=5","date":"2025-10-16","type":"pipeline","source":"The Pharma Letter","summary":"Xuanzhu Bio raises $100 million in oversubscribed Hong Kong IPO - The Pharma Letter","headline":"Xuanzhu Bio raises $100 million in oversubscribed Hong Kong IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPR0YxbVJHOHFRM0hXX3VHWkhOY0sxUHFsSHFCdGZLVXNzWjRsWlh5cWdTaFROWDFHMnBoR2d0ZXF4cDRFekFmNENQOExUeVlKOXh1LTFWa1Y5NWZ6TzVmdmY2ckVRVENZSjFlc0JrYzlpN0hBQWE0ZThCaE1uQUs4R2F4bnJiLW1pbl9nSmhB?oc=5","date":"2025-10-06","type":"pipeline","source":"thebambooworks.com","summary":"BRIEF: Xuanzhu Biopharma launches IPO to raise $100 million - thebambooworks.com","headline":"BRIEF: Xuanzhu Biopharma launches IPO to raise $100 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBlSFFza25yZzBUUzI4dGlsNXI2V0ZmWGN6cEh4ZVBWWGhxNDBqd1c0TUo5LUJObkxhNlhhU2JmcVJPQ3ZsTGRyRUR2eV9JeEpwV2piTlVuMTBmRWdtREY3R2lCR2pUaFRuUmc?oc=5","date":"2025-08-26","type":"pipeline","source":"Yahoo Finance Australia","summary":"Sunshine Lake Pharma Co., Ltd. (6887.HK) valuation measures and financial statistics - Yahoo Finance Australia","headline":"Sunshine Lake Pharma Co., Ltd. (6887.HK) valuation measures and financial statistics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQWnBvT21RR3AxVHRTeWducGNOd1QyaFdiUUE4VUxuRWxIdkdLUnRmLTkyY1JVdGZZUUxqU2l0UmhoU1dDOW4yWDRoZ3B3N1QwblgzS2JBUkkyOUo0T1BnSFB0OWRrMHd6Z1dvdEF6RVhiRU1TcW45akZsNVc5T2EyNFhuaGk?oc=5","date":"2024-12-05","type":"pipeline","source":"thebambooworks.com","summary":"Xuanzhu Biopharm set for spin-off in Hong Kong IPO - thebambooworks.com","headline":"Xuanzhu Biopharm set for spin-off in Hong Kong IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPSUpJTlZLTlhLQmhhRU5kV1pxc0U3MHR6bFpfRm1SbE91YWJaMk02QWkzbFJ0WDI3NGNtYUY5TTlFWUF5WFRyaXVldW9hcjI4MXRXS3djTlVmLVJXWUxNd2VhWkR2R2N5SFdXaEJYVGg3ZXlIX0dTSG02OGM5WlJhekU3NGRYcUJFYXJXXzJ2T3Bmd1pFd2UxaW1FZEFFZw?oc=5","date":"2024-11-25","type":"pipeline","source":"富途牛牛","summary":"Sihuan pharm has spun off \"Xuan Zhu Biotech\" and submitted an IPO prospectus, planning to go public in Hong Kong, with CICC as the exclusive sponsor. - 富途牛牛","headline":"Sihuan pharm has spun off \"Xuan Zhu Biotech\" and submitted an IPO prospectus, planning to go public in Hong Kong, with C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5kRTFuYjdhT0hlMFR3bHJGcFJ0S3d0ZDB1bzN2NDBFY0YwMWlfTk5IbHhRaVA2LTRkZFowcU03Z0NPY3ZDajVxU0NncU5IdzFONklXaURvT3B4M1F0d2hV?oc=5","date":"2024-02-20","type":"regulatory","source":"Nature","summary":"Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA - Nature","headline":"Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5TQzFsQ1NTcGw1Smc2VTlRRm9OUFhmcHIwSTBERnA3ZFdPRDRDdzZRRkVBWWpmUmxzXzNsdktJV0Q1VmlVSXUyXzd4UVFwOEZQaUpTUC1n?oc=5","date":"2017-06-11","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":4,"marketed":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}